TY - JOUR
T1 - Impact of Diabetes in COVID-19 Associated Mucormycosis and its Management
T2 - A Non-Systematic Literature Review
AU - Rashid, Muhammed
AU - Rajan, Asha K.
AU - Thunga, Girish
AU - Shanbhag, Vishal
AU - Nair, Sreedharan
N1 - Funding Information:
This study has been funded by "DSTINSPIRE Fellow-ship", Department of Science and Technology, Government of India, (DST/INSPIRE Fellowship/2019/IF190205) New Delhi, India.Muhammed Rashid would like to acknowledge DST-INSPIRE Fellowship, Department of Science and Technolo-gy, Government of India, New Delhi, India [DST/INSPIRE Fellowship/2019/IF190205] for awarding the fellowship during his doctoral studies (Ph.D). The authors also would like to acknowledge the Academy of Higher Education (MAHE), Manipal College of Pharmaceutical Sciences, Ma-nipal and Department of Pharmacy Practice, for all the support and facilities for the best possible completion of this work.
Funding Information:
Muhammed Rashid would like to acknowledge DST-INSPIRE Fellowship, Department of Science and Technology, Government of India, New Delhi, India [DST/INSPIRE Fellowship/2019/IF190205] for awarding the fellowship during his doctoral studies (Ph.D). The authors also would like to acknowledge the Academy of Higher Education (MAHE), Manipal College of Pharmaceutical Sciences, Ma-nipal and Department of Pharmacy Practice, for all the support and facilities for the best possible completion of this work.
Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2022/4
Y1 - 2022/4
N2 - BACKGROUND: COVID-19 has become extremely dangerous manifesting itself in a variety of forms ranging from a simple flu-like illness to death. COVID-19 associated mucormycosis (CAM) is a global threat with diabetes being a major contributor. OBJECTIVE: This review aims to give a clear picture of the impact of hyperglycemia in CAM along with its management. METHODS: Google and Google Scholar were searched and studies that addressed the impact of diabetes in CAM were considered for this review. We also performed a bibliographic search of the specific article to find additional studies. RESULTS: A series of events such as unregulated activation of innate immune system modification, pro-inflammatory M1 macrophages activation, and the depletion of natural killer cell activity is very common in patients with COVID-19. In addition, the exacerbated cytokine syndrome and hyperinflammatory response may elevate the severity of this condition, which further leads to higher mortality. The impaired immune phase which follows provide the niche for increased infection among diabetic patients making them more prone towards developing mucormycosis and associated infections. Early detection, surgical debridement, and appropriate medical treatment with antifungals and hypoglycaemic agents may help control the infection and associated morbidity and mortality. COVID-19 drugs, hypoglycaemic agents, antifungals, and comorbidities have all been associated with adverse side effects and drug interactions. CONCLUSION: Clinicians should be well aware of this deadly disease and manage COVID-19, diabetes, and mucormycosis through individualized treatment regimens to improve patient outcomes.
AB - BACKGROUND: COVID-19 has become extremely dangerous manifesting itself in a variety of forms ranging from a simple flu-like illness to death. COVID-19 associated mucormycosis (CAM) is a global threat with diabetes being a major contributor. OBJECTIVE: This review aims to give a clear picture of the impact of hyperglycemia in CAM along with its management. METHODS: Google and Google Scholar were searched and studies that addressed the impact of diabetes in CAM were considered for this review. We also performed a bibliographic search of the specific article to find additional studies. RESULTS: A series of events such as unregulated activation of innate immune system modification, pro-inflammatory M1 macrophages activation, and the depletion of natural killer cell activity is very common in patients with COVID-19. In addition, the exacerbated cytokine syndrome and hyperinflammatory response may elevate the severity of this condition, which further leads to higher mortality. The impaired immune phase which follows provide the niche for increased infection among diabetic patients making them more prone towards developing mucormycosis and associated infections. Early detection, surgical debridement, and appropriate medical treatment with antifungals and hypoglycaemic agents may help control the infection and associated morbidity and mortality. COVID-19 drugs, hypoglycaemic agents, antifungals, and comorbidities have all been associated with adverse side effects and drug interactions. CONCLUSION: Clinicians should be well aware of this deadly disease and manage COVID-19, diabetes, and mucormycosis through individualized treatment regimens to improve patient outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85143612504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143612504&partnerID=8YFLogxK
U2 - 10.2174/1573399818666220224123525
DO - 10.2174/1573399818666220224123525
M3 - Short survey
C2 - 35209828
AN - SCOPUS:85143612504
SN - 1573-3998
VL - 19
SP - 1
EP - 10
JO - Current Diabetes Reviews
JF - Current Diabetes Reviews
IS - 3
M1 - e240222201411
ER -
